🎗️ Counting Cancer: Should India Make Cancer a Notifiable Disease?

Thesis

A nation's compassion is only as good as its arithmetic; without reliable numbers, public health drifts from evidence into guesswork, and the invisible go uncared for.

Opening Hook

"You cannot heal what you refuse to count." India estimates its cancer burden while other nations count it — and the gap between an estimate and a count is measured in lives.

Body Structure

• Part I: Data as the foundation of planning — from smallpox surveillance to today's registries.
• Part II: The cost of blind spots — urban-skewed coverage, missing private and rural cases.
• Part III: Notification as a bridge from clinic to policy — stage, survival, targeting.
• Part IV: Guardrails — privacy, proportionality and public trust after Puttaswamy.

Counterargument

"More data can mean more surveillance." Concede the risk — then show that the answer is purpose-limited, de-identified data governed by law, not a retreat into ignorance.

Conclusion

Counting is not cold bureaucracy; it is the first act of care. A society that measures its suffering can finally begin to relieve it.

Thesis

The legitimacy of a health mandate lies not in choosing the public good over private rights, but in calibrating one to protect the other.

Opening Hook

"The law that protects a population must also respect the person." Making an intimate diagnosis reportable is a test of how a republic balances the two.

Body Structure

• The public-health rationale for mandatory reporting and the right to health.
• The privacy dimension — stigma, consent, the DPDP Act and Puttaswamy.
• The federal question — regulating an NCD across a State subject.
• Proportionate design: minimal data, oversight, de-identification, redress.

Conclusion

Rights and regulation are not rivals but partners; the measure of good governance is the proportion it strikes between them.

Thesis

In a union where health is a State subject but disease respects no border, national goals are best met by partnership, not command.

Opening Hook

"A cell divides the same way in every state; only our records draw borders." Cancer's biology is national even where its data are not.

Body Structure

• The constitutional division — State List, Concurrent List and its limits.
• Instruments of cooperation — model laws, conditional grants, common standards.
• The 17-state momentum as bottom-up federalism in action.
• Building shared digital infrastructure without eroding autonomy.

Conclusion

Cooperative federalism turns a jurisdictional puzzle into a shared project — the surest path to a truly national health picture.

Thesis

Prevention and early detection are not merely medical virtues but sound economics; every rupee spent on knowing is a rupee saved on late, catastrophic care.

Opening Hook

"The cheapest cancer to treat is the one caught early — and the one we can see coming." Surveillance is where health economics begins.

Body Structure

• The economic burden of late diagnosis and out-of-pocket spending.
• Surveillance as investment — targeting screening where returns are highest.
• Insurance and workforce planning driven by reliable numbers.
• Cost-effective interventions: tobacco control, HPV vaccination, screening.

Conclusion

Data-led early detection is a growth strategy for a healthy nation — spending wisely today to spare families and budgets tomorrow.

Thesis

The journey of a single diagnosis, when it feeds a shared system, can improve the odds for millions — care and data are two sides of one coin.

Opening Hook

"One patient's record, well kept, becomes another patient's cure." The individual and the collective meet in the registry.

Body Structure

• The clinical encounter — where care and data are created together.
• From records to research — survival studies, treatment-outcome analysis.
• Technology as enabler — EHRs, unique IDs, telepathology.
• Ethics of the digital registry — dignity, security, transparency.

Conclusion

When every diagnosis strengthens the system, medicine becomes not just personal treatment but collective progress.

A notifiable disease is one that, by law, must be reported to a designated public-health authority. When Telangana declared cancer notifiable in April 2026, it required every hospital, clinic, AYUSH facility and pathology or radiology lab to report each diagnosed case to a central portal within a month, with a designated Centre of Excellence validating the data before it reaches the ICMR's national registry.

Its significance is twofold. First, it plugs a real gap: India's registries cover only about 16% of the population and miss much of the private sector and rural India, so our national numbers are estimates rather than counts. Second, Telangana became the seventeenth state to act while the Centre has not — a bottom-up push that keeps pressure on for a national mandate that ICMR has recommended since 2008. It is a concrete step toward turning scattered diagnoses into real-time public-health intelligence.

It can, but the route matters. Public health and hospitals fall under the State List, and the Concurrent-List entry that historically underpins disease notification is limited to infectious or contagious diseases — so it does not neatly cover a non-communicable disease like cancer. A blunt Union law would be constitutionally fraught.

The workable path is cooperative federalism. The Centre can circulate a model law or standard rules for states to adopt, and tie reporting to conditional funding under the National Health Mission or the cancer-control programme, so that money and standards travel together. It can also provide the technical spine — ICD-O coding, interoperable portals, unique IDs for record linkage — and support capacity-building. That respects the federal balance while still building a national picture. The seventeen states already on board give a ready foundation to scale from.

Not inherently, but it must be designed carefully. A cancer diagnosis is deeply personal and can invite stigma or discrimination, so the concern is real. After the Puttaswamy judgment, privacy is a fundamental right and any data collection must satisfy proportionality — a legitimate aim, minimal necessary data, purpose limitation and adequate safeguards.

Applied here, that means collecting only the fields surveillance genuinely needs, de-identifying data in public reports, storing and transmitting them securely under the DPDP Act, 2023, restricting access, and providing grievance redress. Reassuring the public that data will be used solely for public-health purposes is essential to compliance. Done this way, notification serves the collective good — better planning and earlier detection — without sacrificing the dignity and confidentiality of the individual patient.

I would treat resistance as a problem to be solved, not merely penalised. First, I would understand the reasons — usually the reporting burden, workflow disruption or confidentiality worries — through a meeting with hospital administrators, labs and professional bodies.

Then I would lower the friction: a simple, secure digital portal, integration with their existing systems, a short training and a helpdesk, and clear assurance that data are confidential and used only for public health. I would use positive levers — linking timely reporting to empanelment and accreditation — before punitive ones, keeping penalties as a due-process backstop for wilful non-compliance. I would designate a nodal officer, publish anonymised district dashboards to show the value returned, and coordinate with the state and ICMR since the mandate spans levels. Throughout, the goal is complete, good-quality data secured through cooperation rather than coercion.

I would launch a single, interoperable digital notification portal, piloted first in the states that have already made cancer notifiable. Because these seventeen states have the legal mandate in place, the missing piece is a common, easy-to-use reporting channel rather than fresh legislation — so results can come quickly.

The portal would use ICD-O fields, integrate with hospital information systems and PM-JAY empanelment, support unique-ID linkage to death registration, and carry built-in privacy safeguards. I would pair it with rapid training for cancer registrars and pathology staff, a helpdesk, and public dashboards of de-identified data to build trust. A focused pilot with clear metrics — reporting completeness, timeliness and data quality — would generate proof of concept and a template the Centre and other states could adopt, laying the groundwork for eventual national notification.

I would resist framing it as either-or; they are complementary, and a small investment in data multiplies the value of a large investment in treatment. Registries are relatively inexpensive but tell us where the burden is, which cancers are rising, and whether our screening and treatment are working — so scarce treatment resources are placed where they save the most lives.

Spending only on treatment while flying blind risks misallocation: radiotherapy units in the wrong places, screening aimed at the wrong ages, and no way to know if outcomes are improving. So my answer is sequencing, not exclusion — sustain and expand treatment while carving out a modest, protected budget for surveillance, because good data make every treatment rupee work harder. That is prudent public-health economics.